Çocukluk Çağı Baş Ağrılarında Tedavi
Özet
Çocukluk çağı baş ağrıları, doğru tanı ve etkili tedavi için primer ve sekonder nedenlerin dikkatle ayırt edilmesini gerektiren, klinik başvurularda sık karşılaşılan bir durumdur. Tedavi yaklaşımı; yaşam tarzı düzenlemeleri, non-farmakolojik yöntemler ve gerekli durumlarda acil veya koruyucu ilaç uygulamalarını içeren çok yönlü bir stratejiye dayanır. Kırmızı bayrak uyarı semptomlarının taranması ve PedMIDAS gibi skorlama araçlarıyla engellilik düzeyinin belirlenmesi, hastaya özgü en uygun tedavi planının oluşturulmasında kritik rol oynar. İlaç tedavisinin her zaman ilk seçenek olmadığı durumlarda, tamamlayıcı yöntemler ve hasta eğitimi, kronik baş ağrılarının yönetimi ve yaşam kalitesinin artırılması için temel unsurlardır.
Childhood headaches are frequently encountered in clinical practice, necessitating a careful distinction between primary and secondary causes to ensure accurate diagnosis and effective management. The therapeutic approach is multifaceted, incorporating lifestyle modifications, non-pharmacological interventions, and, when necessary, acute or preventive medication strategies. Screening for red flag symptoms and assessing disability levels with tools like PedMIDAS are crucial for developing patient-specific care plans. In cases where pharmacological treatment is not immediately required, integrative therapies and patient education serve as fundamental components for managing chronic headaches and improving overall quality of life.
Referanslar
Canpolat M, Kumandas S. Approach to Child Admitted with Headache and Management of Acute Headaches.Turkiye Klinikleri J Pediatr Sci. 2018;14(1):82-98.
Raucci U, Della Vecchia N, Ossella C, Paolino MC, Villa MP, Reale A, Parisi P. Management of Childhood Headache in the Emergency Department. Review of the Literature. Front Neurol. 2019 Aug 23;10:886.
Whitehouse WP, Agrawal S. Management of children and young people with headache. Arch Dis Child Educ Pract Ed. 2017 Apr;102(2):58-65.
Klein J, Koch T. Headache in Children. Pediatr Rev. 2020 Apr;41(4):159-171.
Ahmed MAS, Martinez A, Cahill D, et al. When to image neurologically normal children with headaches: development of a decision rule. Acta Paediatr 2010;99:940–3.
HeadSmart. http://www.headsmart.org.uk/ (accessed 14 Feb 2015).
Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629–808.
National Institute for Health and Care Excellence (NICE). Diagnosis and management of headaches in young people and adults. September 2012. https://www.nice.org.uk/guidance/ cg150 (accessed 14 Feb 2015).
Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1994; 309:765–9.
Hämäläinen ML, Hoppu K, Santavuori PR. Pain and disability in migraine or other recurrent headache as reported by children. Eur J Neurol. 1996; 3:528–32.
Gelfald AA. Pediatric and adolescent headache. Continuum (Minneap Minn). 2018; 24:1108–36.
Whitehouse WP, Agrawal S. Management of children and young people with headache. Arch Dis Child Educ Pract Ed. 2017; 102:58–65.
Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016; 4:CD005220.
Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo controlled, crossover study. Neurology. 1997; 48:103–7.
Barbanti P1, Grazzi L, Egeo G. Pharmacotherapy for acute migraines in children and adolescents. Expert Opin Pharmacother. 2019; 20:455–63.
Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004; 43:256–62.
Sheridan DC, Laurie A, Pacheco S, Fu R, Hansen ML, Ma OJ, et al. Relative effectiveness of dopamine antagonists for pediatric migraine in the emergency department. Pediatr Emerg Care. 2018; 34:165–8.
Slater SK, Powers SW, O’Brien HL. Migraine in children: presentation, disability and response to treatment. Curr Opin Pediatr. 2018; 30:775–9.
Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache. 1994; 34:578–80.
Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009; 49:106–9. doi: 10.1111/j.1526-4610.2008.01293.x
Hämäläinen ML, Hoppu K, Santavuori PR. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol. 1997; 16:114–7.
Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr eurol. 2017; 66:76–81.
Richer L, Craig W, Rowe B. Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache. 2014; 54:1496–505.
Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005; 45:899–903.
Sheridan D, Sun B, O’Brien P, Hansen M. Intravenous sodium valproate for acute pediatric headache. J Emerg Med. 2015; 49:541–5.
Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided. Neurol Sci. 2013; 34(Suppl 1):S125–8.
Tepper SJ. Opioids should not be used in migraine. Headache. 2012; 52(Suppl 1):30–4.
Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014; 83:1277–84.
Mazer-Amirshahi M, Mullins PM, Rasooly IR, van den Anker J, Pines JM. Trends in prescription opioid use in pediatric emergency department patients. Pediatr Emerg Care. 2014; 30:230–5.
Richardson LP, Fan MY, McCarty CA, Katon W, Edlund M, DeVries A, et al. Trends in the prescription of opioids for adolescents with non-cancer pain. Gen Hosp Psychiatry. 2011; 33:423–8.
Lewis DW, Ashwal S, Dahl G, Dorbad D, Hirtz D, Prensky A, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2002; 59:490–8.
Sheridan DC, Meckler GD. Inpatient pediatric migraine treatment: does choice of abortive therapy affect length of stay? J Pediatr. 2016; 179:211–5.
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med. 2017; 12;376(2):115-124.
Agosti R, Duke RK, Chrubasik JE, Chrubasik S. Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review. Phytomedicine. 2006; 13(9-10):743-6.
D'Onofrio F, Raimo S, Spitaleri D, Casucci G, Bussone G. Usefulness of nutraceuticals in migraine prophylaxis. Neurol Sci. 2017; 38(Suppl 1):117-120.
Wells RE, Beuthin J, Granetzke L. Complementary and Integrative Medicine for Episodic Migraine: an Update of Evidence from the Last 3 Years. Curr Pain Headache Rep. 2019; 21;23(2):10.
Pérez-Muñoz A, Buse DC, Andrasik F. Behavioral Interventions for Migraine. Neurol Clin. 2019; 37(4): 789-813
Yamanaka G, Kanou K, Takamatsu T, Takeshita M, Morichi S, Suzuki S, Ishida Y, Watanabe Y, Go S, Oana S, Kawashima H. Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review. J Clin Med. 2021; 3;10(1):138.
Tseng PT, Yang CP, Su KP, Chen TY, Wu YC, Tu YK, Lin PY, Stubbs B, Carvalho AF, Matsuoka YJ, Li DJ, Liang CS, Hsu CW, Chen YW, Shiue YL. The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res. 2020; 69(2):e12663.
Vural EM, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging. 2014; 31(6):441-51.
O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015; 17(1):326.
Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007; 47(1):73-80.
Ahmed K., Oas K., Mack K., Garza, I. Experience with botulinum toxin A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010; 43: 316–319.
Kabbouche, M., O’Brien, H. and Hershey, A. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012; 12: 114–117.
Fernandes L, Randall M MD FRCP, Idrovo L DMed FRCP. Peripheral nerve blocks for headache disorders. Pract Neurol. 2020 Oct 23:practneurol-2020-002612.
Gfrerer L, Guyuron B. Interface Between Cosmetic and Migraine Surgery. Aesthetic Plast Surg. 2017; 41(5):1096-1099.
O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015; 17(1):326.
Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007; 47(1): 73-80.
